Skip to Content

Aplenzin Approval History

FDA Approved: Yes (First approved April 23, 2008)
Brand name: Aplenzin
Generic name: bupropion hydrobromide
Dosage form: Extended-Release Tablets
Previous Name: BVF-033
Company: Biovail Corporation
Treatment for: Depression, Major Depressive Disorder

Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Development History and FDA Approval Process for Aplenzin

Apr 24, 2008Approval Biovail Receives FDA Approval for Aplenzin (BVF-033)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.